Calcitonin in the treatment of osteoporosis

CMAJ. Canadian Medical Association Journal

Volumn 155, Issue 7, 1996, Pages 962-965

  Siminoski, Kerry ^a   Josse, Robert G ^b,c   Bowyer, Mary ^d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d Osteoporosis Society of Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN;

ARTICLE; BACKACHE; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE MINERAL; CHRONIC PAIN; CLINICAL TRIAL; DRUG EFFICACY; FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; LONG TERM CARE; META ANALYSIS; OSTEOCLAST; OSTEOPOROSIS; PAIN; QUALITY OF LIFE; SKIN DISEASE; VASCULAR DISEASE; VERTEBRA FRACTURE; AGED; CANADA; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; FEMALE; MALE; MEDICAL SOCIETY; MIDDLE AGED; PATHOLOGIC FRACTURE;

AGED; CALCITONIN; CANADA; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; SOCIETIES, MEDICAL;

EID: 0030267621     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Wallach S, Cohn SA, Atkins HL et al. Effect of salmon calcitonin on skeletal mass in osteoporosis. Curr Ther Res 1977;22:556-72.
2. Franceschini R, Bottaro P, Panopoulos C, Messina V. Long-term treatment with salmon calcitonin in postmenopausal osteoporosis. Curr Ther Res 1983;34:795-800.
3. Zorzin L, Capone M. Post-menopausal osteoporosis: therapeutic and side effects of different calcitonins. Curr Ther Res 1984;36:473-82.
4. Palmieri GMA, Pitcock JA, Brown P et al. Effect of calcitonin and vitamin D in osteoporosis. Calcif Tissue Int 1989;45:137-41.
5. Lyritis GP, Tsakalakos N, Magiasis B et al. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int 1991;49:369-72.
6. Ringe JD, Welzel D. Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 1987;33:35-9
7. Pun KK, Chan LW. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 1989;11:205-9.
8. Ljunghall S, Gärdsell P, Johnell O et al. Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study. Calcif Tissue Int 1991;49:17-9.
9. Gennari C, Chlerichetti SM, Bigazzi S et al. Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Ther Res 1985; 38:455-64.
10. Mazzuoli GF, Passen M, Gennari C et al. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 1986;38:3-8.
11. Reginster JY, Denis D, Albert A et al. 1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 1987;2:1481-3.
12. MacIntyre I, Stevenson JC, Whitehead MI et al: Calcitonin for prevention of postmenopausal bone loss. Lancet 1988;1:900-2.
13. Overgaard K, Riis BJ, Christiansen C et al. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 1989;299:477-9.
14. Overgaard K, Riis BJ, Christiansen C et al. Nasal calcitonin for treatment of established osteoporosis. Clin Endrocrinol 1989;30:435-42.
15. Overgaard K, Hansen MA, Nielsen VH et al. Discontinuous calcitonin treatment of established osteoporosis - effects or withdrawal of treatment. Am J Med 1990;89:1-6.
16. Thamsborg G, Storm TL, Sykulski R et al. Effect of different doses of nasal salmon calcitonin on bone mass. Calcif Tissue Int 1991;48:302-7.
17. Fioretti P, Gamiocciani M, Taponeco F et al: Effects of continuous and cyclic nasal calcitonin administration in ovariectomized women. Maturitas 1992;15:225-32.
18. Gennari C, Agnusdel D, Montagnani M et al. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcif Tissue Int 1992;50:381-3.
19. Meschia M, Brincat M, Barbacini P et al. A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif Tissue Int 1993;53:17-20.
20. Reginster JY, Denis D, Deroisy K et al. Long-term (three years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin. J Rone Miner Res 1994;9:69-73.
21. Luengo M, Pun F, Martinez de Osaba MJ et al. Prevention of further bone mass loss by nasal calcitonin m patients on long term glucocorticoid therapy for asthma: a two year follow up study. Thorax 1994;49:1099-102.
22. Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int 1994;55:82-6.
23. Reginster JY, Deroisy R, Lecart MP et al. A. double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med 1995;98:452-8.
24. Overgaard K, Hansen MA, Jensen SB et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992;305:556-61.
25. Civitelli R, Gonnelli S, Zacchei F et al. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 1988;82:1268-74.
26. Rico H, Hernandez ER, Revilla M et al. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 1992;16:131-8.
27. Kanis J, Johnell O, Gullberg B et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992;305:1124-8.